Ocumension Gets Clearance to Start Phase III Study in China of Diabetic Macular Edema Drug
Ocumension Gets Clearance to Start Phase III Study in China of Diabetic Macular Edema Drug
Ocumation獲準在中國啟動糖尿病黃斑水腫藥物的第三階段研究
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊